Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force.

Autor: Kalra S; Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India., Bahendeka S; Department of Internal Medicine, Diabetes & Endocrinology, St. Francis Hospital, Nsambya, Kampala, Uganda., Sahay R; Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India., Ghosh S; Department of Endocrinology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India., Md F; Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh., Orabi A; Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Ramaiya K; Department of Internal Medicine, Hindu Mandal Hospital, Dar es Salaam, Tanzania., Al Shammari S; Department of Endocrinology, Al Jahra Hospital, Al Jahra, Kuwait., Shrestha D; Department of Endocrinology, Norvic International Hospital and Medical College, and Hospital for Advanced Medicine and Surgery, Maharajganj, Kathmandu, Nepal., Shaikh K; Department of Diabetes, Faculty of Internal Medicine, Royal Oman Police Hospital, Muscat, Oman., Abhayaratna S; Department of Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka., Shrestha PK; Department of Medicine, Tribhuvan University Teaching Hospital, Maharajganj, Kathmandu, Nepal., Mahalingam A; Department of Medicine, Teaching Hospital, Jaffna, Sri Lanka., Askheta M; Department of Medicine, Tawam Hospital, Al Ain, UAE., A Rahim AA; Department of Internal Medicine, Diabetes & Metabolism Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt., Eliana F; Department of Internal Medicine, Faculty of Medicine, YARSI University, Jakarta, Indonesia., Shrestha HK; Department of Internal Medicine, Kathmandu University Hospital, Dhulikhel, Nepal., Chaudhary S; Department of Endocrinology, ADK Hospitals, Male, Maldives., Ngugi N; Department of Endocrinology, Kenyatta National Hospital, Nairobi, Kenya., Mbanya JC; Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaounde, Cameroon., Aye TT; Department of Endocrinology, University of Medicine 2, Yangon, Myanmar., Latt TS; Department of Medicine, University of Medicine 2, Yangon, Myanmar., Akanov ZA; Center of Diabetes, Clinic of Internal Diseases, Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan., Syed AR; Department of Endocrinology, Shaukat Khanum Hospital and Research Center, Lahore, Pakistan., Tandon N; Department of Endocrinology, Metabolism and Diabetes, All India Institute of Medical Sciences, Pune, Maharashtra, India., Unnikrishnan AG; Department of Endocrinology and Diabetes, Chellaram Diabetes Institute, Pune, Maharashtra, India., Madhu SV; Department of Medicine, University of Delhi, New Delhi, India., Jawa A; Department of Endocrinology, Diabetes and Metabolism, Wilshire Cardiovascular and Endocrine Center of Excellence, Lahore, Pakistan., Chowdhury S; Department of Endocrinology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India., Bajaj S; Department of Medicine, MLN Medical College, Allahabad, Uttar Pradesh, India., Das AK; Department of General Medicine, Pondicherry Institute of Medical Sciences, Puducherry, India.
Jazyk: angličtina
Zdroj: Indian journal of endocrinology and metabolism [Indian J Endocrinol Metab] 2018 Jan-Feb; Vol. 22 (1), pp. 132-157.
DOI: 10.4103/ijem.IJEM_556_17
Abstrakt: For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles. Furthermore, individualization of treatment, using SUs in combination with other drugs, backed with careful monitoring and patient education, ensures maximum benefits with minimal side effects. The current guidelines, developed by experts from Africa, Asia, and the Middle East, promote the safe and smart use of SUs in combination with other glucose-lowering drugs.
Competing Interests: There are no conflicts of interest.
Databáze: MEDLINE
Externí odkaz: